EAM
UBX

Empery Asset Management’s Unity Biotechnology UBX Stock Holding History

Empery Asset Management’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$1.74M Buy
+441,165
New +$2.78M 10.37% 2

Other funds holding UBX

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Empery Asset Management's UBX Position: Q3 2022 in Review

Empery Asset Management opened a new position in Unity Biotechnology (UBX) in Q3 2022: 441,165 shares worth $1.74M. The stake represents 10.37% of the portfolio and ranks #2 among its holdings.

72 funds tracked by Wall St. Rank hold UBX as of Q3 2022.

  • Empery Asset Management held 441,165 shares of Unity Biotechnology worth $1.74M as of Q3 2022.
  • Unity Biotechnology was a new Empery Asset Management position in Q3 2022.
  • Unity Biotechnology made up 10.37% of Empery Asset Management's portfolio in Q3 2022, its #2 holding.
  • 72 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2022.

Based on Empery Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.